SCHEMBL3052902

SCHEMBL3052902

CCCCc1cccc(CCNC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 4/20 0.59
▸ CHRM2 P08172 1/20 0.56
▸ CHRM1 P11229 1/20 0.56
▸ CHRM3 P20309 1/20 0.56
▸ ATM Q13315 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ SIGMAR1 Q99720 2/20 0.48
▸ MAPT P10636 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ THPO P40225 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ LPL P06858 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906778 0.88 TAAR1 (0.63) TAAR1CHRM2CHRM1CHRM3ATM
SCHEMBL347126 0.85 LPL (0.57) L3MBTL1MAPK1LPLLIPGHPGD
SCHEMBL28151845 0.85 SIGMAR1 (0.65) TAAR1L3MBTL1MEN1KMT2ASIGMAR1
SCHEMBL28313957 0.85 SIGMAR1 (0.59) TAAR1L3MBTL1MEN1KMT2ASIGMAR1
SCHEMBL23938434 0.85 KDM4E (0.47) MAPTCYP1A2LPLLIPGKDM4E
SCHEMBL2911337 0.84 TAAR1 (0.63) TAAR1CHRM2CHRM1CHRM3ATM
SCHEMBL2910424 0.84 TAAR1 (0.59) TAAR1ATML3MBTL1MEN1KMT2A
SCHEMBL5433566 0.84 LPL (0.52) L3MBTL1MAPK1LPLLIPGHPGD
SCHEMBL13463820 0.83 TAAR1 (0.58) TAAR1CHRM2CHRM1CHRM3ATM
SCHEMBL28409443 0.81 LPL (0.53) L3MBTL1MAPK1LPLLIPGHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394979-B2 Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) 2013-03-12 — — US disclosed
US-20100267977-A1 METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) 2010-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267977-A1 METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF THPO, MCL1, PPOX TAAR1 4519/4885CHRM2 4851/4885CHRM1 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback